- Home
- NXP vs NEO Comparison
NXP vs NEO Comparison
Compare NXP & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- NEO
- Stock Information
- Founded
- NXP 1992
- NEO 2001
- Country
- NXP United States
- NEO United States
- Employees
- NXP N/A
- NEO N/A
- Industry
- NXP Trusts Except Educational Religious and Charitable
- NEO Precision Instruments
- Sector
- NXP Finance
- NEO Health Care
- Exchange
- NXP Nasdaq
- NEO Nasdaq
- Market Cap
- NXP 699.7M
- NEO 709.2M
- IPO Year
- NXP N/A
- NEO 1999
- Fundamental
- Price
- NXP $13.96
- NEO $6.21
- Analyst Decision
- NXP
- NEO Buy
- Analyst Count
- NXP 0
- NEO 8
- Target Price
- NXP N/A
- NEO $12.00
- AVG Volume (30 Days)
- NXP 70.0K
- NEO 3.1M
- Earning Date
- NXP 01-01-0001
- NEO 07-29-2025
- Dividend Yield
- NXP 4.04%
- NEO N/A
- EPS Growth
- NXP N/A
- NEO N/A
- EPS
- NXP 0.54
- NEO N/A
- Revenue
- NXP N/A
- NEO $689,189,000.00
- Revenue This Year
- NXP N/A
- NEO $13.83
- Revenue Next Year
- NXP N/A
- NEO $11.35
- P/E Ratio
- NXP $26.81
- NEO N/A
- Revenue Growth
- NXP N/A
- NEO 9.70
- 52 Week Low
- NXP $12.91
- NEO $4.72
- 52 Week High
- NXP $14.89
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- NXP 52.55
- NEO 50.53
- Support Level
- NXP $13.93
- NEO $5.37
- Resistance Level
- NXP $14.04
- NEO $6.34
- Average True Range (ATR)
- NXP 0.08
- NEO 0.39
- MACD
- NXP 0.01
- NEO 0.13
- Stochastic Oscillator
- NXP 74.19
- NEO 91.98
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.